Acetaminophen and Topical NSAIDs — First-Line OA Therapy
First-line therapy for mild osteoarthritis pain and stiffness.
- 0–3: Pain score range (mild, intermittent)
- Acetaminophen: First-line agent (≤3g/day max)
- Diclofenac gel: Topical option (localized joints only)
- Minimal: GI risk (no systemic NSAID exposure)
Acetaminophen dosing and limits
Scheduled dosing controls mild pain safely.
Topical NSAIDs for localized joints
Topical diclofenac targets knees and hands directly.
Monitoring for step-up need
Reassess pain and function every four weeks.
Non-drug measures — exercise, weight loss — start here too.
Oral NSAIDs — Adding Systemic Anti-Inflammatory Coverage
Oral NSAIDs added when topical therapy is insufficient.
- 4–6: Pain score range (moderate, activity-limiting)
- Naproxen / Ibuprofen: Common agent (scheduled, lowest effective dose)
- PPI co-therapy: GI protection (if GI risk elevated)
- eGFR checked: Renal monitoring (baseline and periodic)
Oral NSAID selection
Choose lowest effective dose for shortest duration.
GI and renal risk mitigation
PPI co-prescription reduces ulcer risk substantially.
Response assessment window
Six weeks typical before judging response adequacy.
Persistent moderate pain past six weeks signals inadequate response.
Dose Optimization and Combination Therapy
Insufficient relief prompts dose review and combination strategies.
- No response: Trigger (>6 weeks on oral NSAID)
- Combination therapy: Strategy (NSAID + acetaminophen + topical)
- Intra-articular injection: Adjunct (corticosteroid or hyaluronic acid)
- Every 4 weeks: Reassessment (track functional outcomes)
Dose and agent optimization
Switching NSAID class sometimes restores adequate relief.
Adding intra-articular injections
Corticosteroid injections provide short-term flare relief.
Multimodal combination approach
Layering non-drug therapy improves overall pain control.
Physical therapy and weight management remain essential throughout.
Short-Course Opioid Consideration for Severe Pain
Severe pain may warrant brief, closely monitored opioid use.
- 7–8: Pain score range (severe, disabling)
- Short-term only: Opioid course (days to weeks, not chronic)
- Required: Risk screening (misuse and dependence history)
- Mandatory: Tapering plan (defined exit strategy upfront)
Patient selection criteria
Reserve opioids for severe, refractory, disabling pain only.
Risk-benefit and screening
Screen for substance use risk before prescribing.
Tapering and exit strategy
Plan discontinuation before the first prescription begins.
Opioids are a bridge, never a long-term OA solution.
Referral to Surgical Options for Refractory Disease
Refractory pain despite full therapy warrants surgical referral.
- 9–10: Pain score range (refractory, unrelenting)
- Advanced OA: Imaging (confirmed on radiograph/MRI)
- Arthroplasty: Surgical options (total or partial joint replacement)
- High success: Outcome (>90% patient satisfaction reported)
When surgery becomes appropriate
Failed conservative therapy defines the surgical threshold.
Joint replacement options
Total or partial arthroplasty restores joint function.
Post-surgical expectations
Rehabilitation restores mobility over several months.
Surgical referral is a treatment success, not a failure.